bortezomib,lenalidomide,dexamethasone,daratumumab
amgen,janssen,takeda
['mmsm', 'griffin']
rebecca silbermann, md, mms, discusses the findings of the phase 2 griffin study which were presented at the 2022 ash annual meeting. #ash22 #mmsm | 
Oncology news and insights from leading researchers and cancer centers.